Board of Directors



Mr. Chaim Hurvitz has been the Chief Executive Officer of CH Health since May 2011. He previously served as the President of Teva International Group at Teva Pharmaceutical Industries Ltd from April 2002 to 2010 was a Director and member of the senior management of Teva Pharmaceuticals Industries Ltd. He serves as the Chairman of Galmed Pharmaceuticals Ltd. and has been its Director since 2011. He has been a Director of TheraCoat Ltd. since October 2010. He is a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which was awarded in 1985.




Co-founder and Chair, Scientific Advisory Board


Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuro-psychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.




James Lawrence served as the Chief Executive Officer and subsequently Chairman of Global Investment Banking at Rothschild North America Inc., from 2010 to 2015. Previously, he served as the Chief Financial Officer of Unilever, General Mills in 1998, and Northwest Airlines. He served as a President and Chief Executive Officer of Pepsi-Cola International.  Jim was a Partner of Bain and Company and headed its London and Munich offices. He co-founded LEK Consulting in 1982. Jim’s involvement with health care includes service as a Director of Allina Health System, Inc., TransTechnology Corp., Allina Hospitals & Clinics, Physicians Formula Holdings Inc., and Intuitive Surgical, Inc. Mr. Lawrence received his Bachelor of Arts Degree in Economics from Yale University in 1974 and has an MBA with distinction from Harvard Business School in 1976.



Dr. Glied, whose principal areas of research are in health policy reform and mental health care policy, was named Dean of New York University’s Robert F. Wagner Graduate School of Public Service in 2013.  From 1989-2013, Dr. Glied was professor of health policy and management at Columbia University’s Mailman School of Public Health and served as chair of the department of health policy and management from 1998-2009.  In 2010, Dr. Glied was confirmed by the U.S. Senate as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services, serving in that capacity from July 2010 through August 2012. She had previously served as senior economist for health care and labor market policy on the President’s Council of Economic Advisers in 1992-1993, under Presidents Bush and Clinton, and participated in the Clinton Health Care Task Force.



Aaron Gorovitz, J.D.


Aaron Gorovitz is a partner of Lowndes, Drosdick, Doster, Kantor, and Reed, of Orlando, FL. He is a graduate of Muhlenberg College and the George Washington University School of Law. In addition to his 25 years of legal experience in complex commercial transactions, he has considerable involvement in early stage biotechnology and health information technology companies.

© 2016 NeuroRx, Inc.

*This drug is investigational and not approved by the US FDA